clinical trial · NCT04805671
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
COVID-19ADG20Normal saline
brief summary
This placebo controlled study is intended to generate safety and efficacy data in order to provide a treatment option for COVID-19 in patients with a high risk of disease progression based on age or co-morbid medical conditions.
started
Jul 26, 2021
primary completion
Feb 10, 2022
completion
Nov 3, 2022
last updated
Feb 6, 2024
official title
A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ADG20 in the Treatment of Ambulatory Participants With Mild or Moderate COVID-19 (STAMP)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol